EP0625049A4 - Ex vivo gene transfer. - Google Patents

Ex vivo gene transfer.

Info

Publication number: EP0625049A4
Authority: EP; European Patent Office
Prior art keywords: gene transfer; vivo gene; vivo; transfer; gene
Prior art date: 1992-01-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP93904539A

Other languages

German (de)

French (fr)

Other versions

EP0625049A1 (en

Inventor

Gary H Rhodes

Varavani J Dwarki

Philip L Las Palomas Felgner

Jiin-Yu Las Palo Hwang-Felgner

Marston Manthorpe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fresh Tracks Therapeutics Inc

Original Assignee

Vical Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-23

Filing date

1993-01-21

Publication date

1995-07-12

1993-01-21 Application filed by Vical Inc filed Critical Vical Inc

1994-11-23 Publication of EP0625049A1 publication Critical patent/EP0625049A1/en

1995-07-12 Publication of EP0625049A4 publication Critical patent/EP0625049A4/en

Status Withdrawn legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Virology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Dispersion Chemistry (AREA)
Psychology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Biotechnology (AREA)
Neurology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP93904539A 1992-01-23 1993-01-21 Ex vivo gene transfer. Withdrawn EP0625049A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US82437092A	1992-01-23	1992-01-23
US824370		1992-01-23
PCT/US1993/000492 WO1993014778A1 (en)	1992-01-23	1993-01-21	Ex vivo gene transfer

Publications (2)

Publication Number	Publication Date
EP0625049A1 EP0625049A1 (en)	1994-11-23
EP0625049A4 true EP0625049A4 (en)	1995-07-12

Family

ID=25241222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP93904539A Withdrawn EP0625049A4 (en)	1992-01-23	1993-01-21	Ex vivo gene transfer.

Country Status (4)

Country	Link
EP (1)	EP0625049A4 (en)
JP (1)	JPH07503372A (en)
CA (1)	CA2128616A1 (en)
WO (1)	WO1993014778A1 (en)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5538722A (en) *	1989-06-13	1996-07-23	Stanford University	Isolation, growth, differentiation and genetic engineering of human muscle cells
US5693769A (en) *	1991-12-13	1997-12-02	Transcell Technologies, Inc.	Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5795870A (en) *	1991-12-13	1998-08-18	Trustees Of Princeton University	Compositions and methods for cell transformation
US5792751A (en) *	1992-04-13	1998-08-11	Baylor College Of Medicine	Tranformation of cells associated with fluid spaces
US5928944A (en) *	1994-02-04	1999-07-27	The United States Of America As Represented By The Department Of Health And Human Services	Method of adenoviral-medicated cell transfection
US6075012A (en) *	1994-02-11	2000-06-13	Life Technologies, Inc.	Reagents for intracellular delivery of macromolecules
US6989434B1 (en)	1994-02-11	2006-01-24	Invitrogen Corporation	Reagents for intracellular delivery of macromolecules
US6911216B1 (en)	1994-10-12	2005-06-28	Genzyme Corporation	Targeted delivery via biodegradable polymers
US5830878A (en) *	1995-06-07	1998-11-03	Megabios Corporation	Cationic lipid: DNA complexes for gene targeting
US6537776B1 (en)	1999-06-14	2003-03-25	Diversa Corporation	Synthetic ligation reassembly in directed evolution
US5783566A (en) *	1996-05-10	1998-07-21	California Institute Of Technology	Method for increasing or decreasing transfection efficiency
AU3514197A (en)	1996-07-03	1998-01-21	Genetics Institute Inc.	Protease fmh-1, an ice/ced-like protease
US7384923B2 (en)	1999-05-14	2008-06-10	Lipoxen Technologies Limited	Liposomes
EP1254657B1 (en)	1996-09-13	2008-05-21	Lipoxen Technologies Limited	Liposomes
US6197332B1 (en)	1997-08-13	2001-03-06	Chiron Corporation	Lipid-conjugated polyamide compounds and related compositions and methods thereof
CN1263854C (en)	1997-11-06	2006-07-12	启龙股份公司	Neisserial antigens
US6914131B1 (en)	1998-10-09	2005-07-05	Chiron S.R.L.	Neisserial antigens
DE69941567D1 (en)	1998-01-14	2009-12-03	Novartis Vaccines & Diagnostic	ANTIGENE FROM NEISSERIA MENINGITIDIS
EP2261344A3 (en)	1998-05-01	2012-01-04	Novartis Vaccines and Diagnostics, Inc.	Neisseria meningitidis antigens and compositions
WO2000027795A1 (en)	1998-11-12	2000-05-18	Invitrogen Corporation	Transfection reagents
ES2477194T3 (en)	1999-04-30	2014-07-16	Novartis Vaccines And Diagnostics S.R.L.	Neisserial antigens conserved
GB9911683D0 (en)	1999-05-19	1999-07-21	Chiron Spa	Antigenic peptides
GB9916529D0 (en)	1999-07-14	1999-09-15	Chiron Spa	Antigenic peptides
ES2541830T3 (en)	1999-10-29	2015-07-27	Novartis Vaccines And Diagnositics S.R.L.	Neisseria antigenic peptides
DK1248647T3 (en)	2000-01-17	2010-09-27	Novartis Vaccines & Diagnostic	Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
EP1261723B1 (en)	2000-02-28	2008-02-27	Novartis Vaccines and Diagnostics S.r.l.	Hybrid expression of neisserial proteins
US7700359B2 (en)	2000-06-02	2010-04-20	Novartis Vaccines And Diagnostics, Inc.	Gene products differentially expressed in cancerous cells
ATE397094T1 (en)	2000-06-15	2008-06-15	Novartis Vaccines & Diagnostic	POLYNUCLEOTIDES FOR DETERMINING COLON CANCER
NZ593617A (en)	2000-10-27	2012-04-27	Novartis Vaccines & Diagnostic	Nucleic acids and proteins from streptococcus groups A & B
WO2002046477A2 (en)	2000-12-07	2002-06-13	Chiron Corporation	Endogenous retroviruses up-regulated in prostate cancer
WO2002066076A1 (en) *	2001-02-21	2002-08-29	Melbourne Neuromuscular Research Institute	A method of treatment and agents useful for same
GB0107661D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
GB0107658D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Streptococcus pneumoniae
DE50214200D1 (en)	2001-06-05	2010-03-25	Curevac Gmbh	Stabilized tumor antigen mRNA with increased G / C content
AU2002366592B2 (en)	2001-12-12	2008-01-10	Novartis Vaccines And Diagnostics S.R.L.	Immunisation against Chlamydia trachomatis
DE10162480A1 (en)	2001-12-19	2003-08-07	Ingmar Hoerr	The application of mRNA for use as a therapeutic agent against tumor diseases
AU2003235791A1 (en)	2002-01-08	2003-07-24	Chiron Corporation	Gene products differentially expressed in cancerous breast cells and their methods of use
US20040023267A1 (en)	2002-03-21	2004-02-05	Morris David W.	Novel compositions and methods in cancer
US8518694B2 (en)	2002-06-13	2013-08-27	Novartis Vaccines And Diagnostics, Inc.	Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
US20070059329A1 (en)	2002-11-15	2007-03-15	Nathalie Norais	Unexpected surface proteins in meningococcus
US20040170982A1 (en)	2003-02-14	2004-09-02	Morris David W.	Novel therapeutic targets in cancer
EP2058408A3 (en)	2003-02-14	2009-09-09	Sagres Discovery, Inc.	Therapeutic GPCR targets in cancer
US7767387B2 (en)	2003-06-13	2010-08-03	Sagres Discovery, Inc.	Therapeutic targets in cancer
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
DE10335833A1 (en) *	2003-08-05	2005-03-03	Curevac Gmbh	Transfection of blood cells with mRNA for immune stimulation and gene therapy
US20060024677A1 (en)	2004-07-20	2006-02-02	Morris David W	Novel therapeutic targets in cancer
WO2006110599A2 (en)	2005-04-07	2006-10-19	Novartis Vaccines And Diagnostics Inc.	Cacna1e in cancer diagnosis, detection and treatment
EP2083088A3 (en)	2005-04-07	2009-10-14	Novartis Vaccines and Diagnostics, Inc.	Cancer-related genes
DK2054431T3 (en)	2006-06-09	2012-01-02	Novartis Ag	Conformers of bacterial adhesins
PL2425016T3 (en)	2009-04-29	2015-09-30	Academisch Medisch Centrum Bij De Univ Van Amsterdam	Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
WO2011056073A2 (en)	2009-11-04	2011-05-12	Erasmus University Medical Center Rotterdam	Novel compounds for modulating neovascularisation and methods of treatment using these compounds
CU23896B1 (en)	2010-04-01	2013-05-31	Ct De Ingeniería Genética Y Biotecnología	METHOD FOR INHIBITING THE REPLICATION OF HIV IN CELLS OF MAMMALS
EP2390346A1 (en)	2010-05-28	2011-11-30	Universiteit Twente	Osteoarthrosis markers
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
CA3162352A1 (en)	2010-10-01	2012-04-05	Modernatx, Inc.	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2012105826A1 (en)	2011-02-01	2012-08-09	Erasmus University Medical Center Rotterdam	Use of micrornas in diagnosis and therapy of aging
DE12722942T1 (en)	2011-03-31	2021-09-30	Modernatx, Inc.	RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
HUE057725T2 (en)	2011-10-03	2022-06-28	Modernatx Inc	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RS63244B1 (en)	2011-12-16	2022-06-30	Modernatx Inc	Modified mrna compositions
SG11201404741VA (en)	2012-02-07	2014-09-26	Global Bio Therapeutics Usa Inc	Compartmentalized method of nucleic acid delivery and compositions and uses thereof
AU2013243950A1 (en)	2012-04-02	2014-10-30	Moderna Therapeutics, Inc.	Modified polynucleotides
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
ES2921623T3 (en)	2012-11-26	2022-08-30	Modernatx Inc	terminally modified RNA
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
ES2733911T3 (en)	2013-08-08	2019-12-03	Global Bio Therapeutics Inc	Clamping device for minimally invasive procedures
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
CN105980401A (en)	2013-10-03	2016-09-28	现代治疗公司	Polynucleotides encoding low density lipoprotein receptor
CA2925021A1 (en)	2013-11-01	2015-05-07	Curevac Ag	Modified rna with decreased immunostimulatory properties
CN106572974B (en)	2014-07-15	2021-04-23	生命技术公司	Compositions and methods having lipid aggregates for efficient delivery of molecules to cells
US11364292B2 (en)	2015-07-21	2022-06-21	Modernatx, Inc.	CHIKV RNA vaccines
EP4218805A1 (en)	2015-07-21	2023-08-02	ModernaTX, Inc.	Infectious disease vaccines
EP3350157B1 (en)	2015-09-17	2022-01-05	Modernatx, Inc.	Compounds and compositions for intracellular delivery of therapeutic agents
MA46316A (en)	2015-10-22	2021-03-24	Modernatx Inc	HUMAN CYTOMEGALOVIRUS VACCINE
EP4349404A3 (en)	2015-10-22	2024-06-19	ModernaTX, Inc.	Respiratory virus vaccines
EP3364950A4 (en)	2015-10-22	2019-10-23	ModernaTX, Inc.	Tropical disease vaccines
US10799463B2 (en)	2015-12-22	2020-10-13	Modernatx, Inc.	Compounds and compositions for intracellular delivery of agents
EP3528821A4 (en)	2016-10-21	2020-07-01	ModernaTX, Inc.	Human cytomegalovirus vaccine
WO2018089540A1 (en)	2016-11-08	2018-05-17	Modernatx, Inc.	Stabilized formulations of lipid nanoparticles
EP3551193A4 (en)	2016-12-08	2020-08-19	Modernatx, Inc.	Respiratory virus nucleic acid vaccines
EP3582790A4 (en)	2017-02-16	2020-11-25	ModernaTX, Inc.	High potency immunogenic compositions
US11969506B2 (en)	2017-03-15	2024-04-30	Modernatx, Inc.	Lipid nanoparticle formulation
CN110520409A (en)	2017-03-15	2019-11-29	摩登纳特斯有限公司	Compound and composition for Intracellular delivery therapeutic agent
AU2018234814B2 (en)	2017-03-15	2022-06-30	Modernatx, Inc.	Crystal forms of amino lipids
MA47790A (en)	2017-03-17	2021-05-05	Modernatx Inc	RNA-BASED VACCINES AGAINST ZOONOTIC DISEASES
WO2018232120A1 (en)	2017-06-14	2018-12-20	Modernatx, Inc.	Compounds and compositions for intracellular delivery of agents
US11786607B2 (en)	2017-06-15	2023-10-17	Modernatx, Inc.	RNA formulations
AU2018326799A1 (en)	2017-08-31	2020-02-27	Modernatx, Inc.	Methods of making lipid nanoparticles
EP3681514A4 (en)	2017-09-14	2021-07-14	ModernaTX, Inc.	Zika virus rna vaccines
CA3113651A1 (en)	2018-09-20	2020-03-26	Modernatx, Inc.	Preparation of lipid nanoparticles and methods of administration thereof
US11351242B1 (en)	2019-02-12	2022-06-07	Modernatx, Inc.	HMPV/hPIV3 mRNA vaccine composition
WO2020190750A1 (en)	2019-03-15	2020-09-24	Modernatx, Inc.	Hiv rna vaccines
TW202124360A (en)	2019-09-19	2021-07-01	美商現代公司	Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US11406703B2 (en)	2020-08-25	2022-08-09	Modernatx, Inc.	Human cytomegalovirus vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991016024A1 (en) *	1990-04-19	1991-10-31	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules

1993
- 1993-01-21 EP EP93904539A patent/EP0625049A4/en not_active Withdrawn
- 1993-01-21 WO PCT/US1993/000492 patent/WO1993014778A1/en not_active Application Discontinuation
- 1993-01-21 JP JP5513303A patent/JPH07503372A/en active Pending
- 1993-01-21 CA CA 2128616 patent/CA2128616A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991016024A1 (en) *	1990-04-19	1991-10-31	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MALONE R.W. ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, no. 16, pages 6077 - 6081 *
See also references of WO9314778A1 *

Also Published As

Publication number	Publication date
WO1993014778A1 (en)	1993-08-05
CA2128616A1 (en)	1993-08-05
EP0625049A1 (en)	1994-11-23
JPH07503372A (en)	1995-04-13

Legal Events

Date	Code	Title	Description
1994-10-07	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1994-11-23	17P	Request for examination filed	Effective date: 19940817
1994-11-23	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
1995-07-12	A4	Supplementary search report drawn up and despatched
1995-07-12	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
1995-07-12	RHK1	Main classification (correction)	Ipc: C12N 5/10
1997-01-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
1997-03-12	18D	Application deemed to be withdrawn	Effective date: 19950731

Publication	Publication Date	Title
EP0625049A4 (en)	1995-07-12	Ex vivo gene transfer.
EP0597463A3 (en)	1996-11-06	Thermotherapiesonde.
EP0635369A3 (en)	1995-06-14	Intermediate transfer surface application system.
IL117691A0 (en)	1996-07-23	Gene transfer into the kidney
EP0580285A3 (en)	1995-05-03	Auto-reclosers.
EP0629817A3 (en)	1995-05-31	Furnace.
EP0516958A3 (en)	1993-07-21	Caffeoyl-coa-3-o-methyltransferase gene
ZA93110B (en)	1993-07-14	Probiotic agent.
EP0647707A3 (en)	1997-05-21	Incubator.
EP0572808A3 (en)	1995-05-31	Antiblocage-system.
ZA971272B (en)	1997-08-27	Gene expression.
GB9306386D0 (en)	1993-05-19	Gene expression
EP0613264A3 (en)	1995-11-08	Group modulator.
EP0595308A3 (en)	1995-05-17	Rapid exchange catheter.
EP0654358A3 (en)	1997-03-19	Transfer printer.
EP0684153A4 (en)	1996-05-08	Transfer construction.
EP0667314A4 (en)	1996-01-31	Continuous transfer apparatus.
GB9201624D0 (en)	1992-03-11	Embryon embryo transfer catheter
EP0599191A3 (en)	1995-02-08	Speed-governor-circuit.
EP0603541A3 (en)	1994-11-09	Releasable connector.
EP0672966A3 (en)	1995-12-13	Transfer apparatus.
PH31659A (en)	1999-01-12	Therapeutic nucleotides.
EP0592354A3 (en)	1994-11-09	Vacuum-centrifuge.
EP0586848A3 (en)	1995-01-25	Implant.
EP0581244A3 (en)	1994-12-21	Transfer film.